Patients who continued to receive pembrolizumab-based therapy after disease progression had longer overall survival than patients who stopped receiving pembrolizumab-based therapy.

During a Community Case Forum event, Stacey Stein, MD, discussed data guiding the use of current regimens for the treatment ...